Scarica l'app Stockscreener
124.67
0.19%
0.24
Dopo l'orario di chiusura:
123.74
-0.93
-0.75%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$124.43
Aprire:
$125.14
Volume 24 ore:
4.86M
Relative Volume:
0.85
Capitalizzazione di mercato:
$216.98B
Reddito:
$43.84B
Utile/perdita netta:
$13.94B
Rapporto P/E:
15.59
EPS:
7.9979
Flusso di cassa netto:
$6.78B
1 W Prestazione:
-1.32%
1M Prestazione:
-6.34%
6M Prestazione:
-4.47%
1 anno Prestazione:
+8.93%
Intervallo 1D:
$124.33
$126.43
Intervallo di 1 settimana:
$124.12
$128.45
Portata 52W:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
124.67 | 216.57B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
100.57 | 148.62B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
368.98 | 141.30B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
90.97 | 117.65B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.48 | 48.55B | 5.69B | 1.41B | 577.90M | 6.9828 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Global Cardiac Monitoring Devices Market to Cross USD 30 Billion by 2032, Driven by Telehealth and Remote Monitoring Trends | DelveInsight - GlobeNewswire Inc.
Daymark Wealth Partners LLC Boosts Stock Holdings in Abbott Laboratories $ABT - MarketBeat
The Zacks Analyst Blog Highlights International Business Machines, Micron and Abbott - sharewise.com
Analyst IMS Investment Management Services Ltd. Decreases Stake in Abbott Laboratories $ABT - MarketBeat
Whalen Wealth Management Inc. Purchases New Position in Abbott Laboratories $ABT - MarketBeat
Jennison Associates LLC Grows Stock Position in Abbott Laboratories $ABT - MarketBeat
Patient sues Abbott after early heart valve replacement - Cardiovascular Business
Top Stock Reports for IBM, Micron & Abbott - Yahoo Finance
Abbott Trifecta Heart Valve Lawsuit Filed Over Device Failure, Removal - AboutLawsuits.com
Is Abbott Laboratories stock a buy in volatile markets2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - newser.com
Mizuho Markets Americas LLC Sells 8,006 Shares of Abbott Laboratories $ABT - MarketBeat
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $162 - 富途牛牛
Abbott Laboratories (ABT): Evaluating Its Valuation Following Recent Share Price Pullback - simplywall.st
How Abbott Laboratories stock reacts to inflationary pressuresWeekly Risk Report & AI Forecasted Stock Moves - Fundação Cultural do Pará
Data supports Abbott Tendyne mitral valve replacement - MassDevice
Is Abbott Laboratories stock a good choice for value investors2025 Geopolitical Influence & AI Forecasted Stock Moves - Fundação Cultural do Pará
Technical signs of recovery in Abbott LaboratoriesMarket Volume Summary & Target Return Focused Stock Picks - newser.com
What makes Abbott Laboratories stock attractive to growth fundsM&A Rumor & Risk Adjusted Buy and Sell Alerts - Fundação Cultural do Pará
Will Abbott Laboratories (ABL) stock maintain strong growth2025 Market Overview & Community Consensus Stock Picks - newser.com
Abbott Laboratories, facing hundreds of lawsuits over safety of formula for premature babies, notches a win in federal court - Slipcase
Abbott’s New Study on Dydrogesterone: A Potential Game-Changer for Endometriosis Pain - TipRanks
Is Abbott Laboratories (Common Stock) (ABL0) stock a buy for dividend portfoliosJuly 2025 Price Swings & Precise Buy Zone Identification - Fundação Cultural do Pará
Abbott Laboratories wins Illinois court case on NEC baby formula claims - Global Food Industry News
Using R and stats models for Abbott Laboratories forecastingWeekly Market Summary & Real-Time Volume Triggers - newser.com
Abbott Laboratories $ABT Shares Sold by Curat Global LLC - MarketBeat
Ashton Thomas Private Wealth LLC Raises Stake in Abbott Laboratories $ABT - MarketBeat
What is the fair value estimate for Abbott Laboratories (ABL) stock in 20252025 Institutional Moves & Short-Term Trading Alerts - newser.com
Will a bounce in Abbott Laboratories offer an exitSwing Trade & High Conviction Investment Ideas - newser.com
Abbott Laboratories (ABT) Surged Ahead of the Market in 2025 with Steady Earnings Momentum - MSN
Abbott Laboratories wins lawsuit over safety of baby formula - Chicago Tribune
Abbott Wins Third Bellwether as Judge Rules Human-Milk Alternative ‘Unfeasible’ - USA Herald
Abbott Wins Third Bellwether In Cow Milk Baby Formula MDL - Law360
Abbott wins third of four 'bellwether' infant formula lawsuits - Crain's Chicago Business
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $145 - 富途牛牛
Protein Bar Market Size, Share, and Growth 2025-2035 | Abbott - openPR.com
Abbott Can't Expand Glucose Monitor Sales Ban At UPC - Law360
Abbott Laboratories (ABT): Exploring Valuation After a Recent Share Price Pullback - Yahoo Finance
Meet RFK’s Corporate Underlings - The American Prospect
Is Abbott Laboratories stock dividend growth reliableJuly 2025 Catalysts & Smart Swing Trading Alerts - newser.com
How Abbott’s Innovative Partnerships Are Shaping Its 2025 Valuation Amid 12.8% YTD Gain - simplywall.st
United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall - GlobeNewswire
1 Safe-and-Steady Stock with Exciting Potential and 2 We Question - The Globe and Mail
Synlait Milk Confirms Investment Regulator's Approval for Abbott's Acquisition of North Island Assets - MarketScreener
Dechert Advises the Shareholders of LARALAB GmbH on ... - Dechert
A Look Into Abbott Laboratories Inc's Price Over Earnings - Sahm
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
The 5 Most Interesting Analyst Questions From Abbott Laboratories’s Q3 Earnings Call - Yahoo Finance
How Abbott Laboratories stock compares to growth peersMarket Movement Recap & Free Weekly Watchlist of Top Performers - newser.com
Can Abbott Laboratories (Common Stock) (ABL0) stock sustain margin levelsGap Down & Entry and Exit Point Strategies - newser.com
Is Abbott Laboratories (ABL) stock cheap by valuation metricsTake Profit & Risk Adjusted Buy/Sell Alerts - newser.com
Is Abbott Laboratories showing signs of accumulationMarket Movement Recap & Expert Approved Momentum Ideas - newser.com
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):